Largest pharmaceutical companies by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Spyre Therapeutics has the lowest figure of the 52 pharmaceutical companies ranked by revenue, at CHF 0, followed by Praxis Precision Medicines (CHF 0) and Dianthus Therapeutics (CHF 1.7M). Figures as of 18 Nov 2026, 20:50 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 52
- Lowest
- Spyre TherapeuticsCHF 0
- Median
- CHF 2.7B
- Combined market value
- CHF 4.27T
- Countries
- 10
- Not ranked
- 9no revenue on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Revenue ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Spyre TherapeuticsSYRE · Health Care | CHF 0 | CHF 8.1B | CHF 85.60 | 8.21% up | 286% up | ||
| 2 | Praxis Precision MedicinesPRAX · Health Care | CHF 0 | CHF 7.2B | CHF 258.81 | 0.61% up | 61% up | ||
| 3 | Dianthus TherapeuticsDNTH · Health Care | CHF 1.7M | CHF 4B | CHF 70.76 | 3.53% down | 113% up | ||
| 4 | Roivant SciencesROIV · Health Care | CHF 7M | CHF 23.6B | CHF 32.63 | 0.05% down | 90% up | ||
| 5 | Protagonist TherapeuticsPTGX · Health Care | CHF 38.8M | CHF 7B | CHF 106.87 | 1.65% up | 46% up | ||
| 6 | CytokineticsCYTK · Health Care | CHF 74.2M | CHF 6B | CHF 43.21 | 0.78% down | 20% down | ||
| 7 | Rhythm PharmaceuticalsRYTM · Health Care | CHF 160M | CHF 7B | CHF 100.62 | 2.33% up | 13% up | ||
| 8 | Ligand PharmaceuticalsLGND · Health Care | CHF 226.1M | CHF 5B | CHF 251.94 | 1.68% up | 43% up | ||
| 9 | Travere TherapeuticsTVTX · Health Care | CHF 413.8M | CHF 4.1B | CHF 42.21 | 2.04% down | 44% up | ||
| 10 | BridgeBio PharmaBBIO · Health Care | CHF 423.4M | CHF 12.8B | CHF 65.51 | 1.15% up | 17% up | ||
| 11 | Mirum PharmaceuticalsMIRM · Health Care | CHF 439.6M | CHF 5.1B | CHF 77.71 | 0.22% up | 31% up | ||
| 12 | InsmedINSM · Health Care | CHF 511.4M | CHF 22.1B | CHF 100.92 | 1.79% down | 40% down | ||
| 13 | TG TherapeuticsTGTX · Health Care | CHF 519.7M | CHF 8.4B | CHF 55.66 | 5.25% up | 107% up | ||
| 14 | Axsome TherapeuticsAXSM · Health Care | CHF 538.4M | CHF 5.9B | CHF 112.63 | 1.76% down | 7% down | ||
| 15 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | CHF 571.4M | CHF 6.3B | CHF 79.95 | 0.32% down | 126% up | ||
| 16 | Corcept TherapeuticsCORT · Health Care | CHF 642.1M | CHF 6.3B | CHF 57.19 | 3.21% down | 8% down | ||
| 17 | Ascendis PharmaASND · Health Care | CHF 673.8M | CHF 14.9B | CHF 227.76 | 0.41% down | 28% up | ||
| 18 | Arrowhead PharmaceuticalsARWR · Health Care | CHF 699.4M | CHF 5.1B | CHF 36.41 | 0.43% up | 10% up | ||
| 19 | Ionis PharmaceuticalsIONS · Health Care | CHF 795.8M | CHF 3.9B | CHF 23.31 | 2.52% up | 64% down | ||
| 20 | Madrigal PharmaceuticalsMDGL · Health Care | CHF 808.2M | CHF 7.8B | CHF 333.94 | 6.16% down | 24% down | ||
| 21 | Legend BiotechLEGN · Health Care | CHF 867.6M | CHF 2.7B | CHF 13.80 | 1.55% up | 42% down | ||
| 22 | AlkermesALKS · Health Care | CHF 1.2B | CHF 6.6B | CHF 39.43 | 2.87% up | 58% up | ||
| 23 | PTC TherapeuticsPTCT · Health Care | CHF 1.5B | CHF 4.2B | CHF 50.61 | 0.57% down | 20% down | ||
| 24 | Royalty PharmaRPRX · Health Care | CHF 2B | CHF 33.3B | CHF 57.88 | 0.06% down | 78% up | ||
| 25 | Amneal PharmaceuticalsAMRX · Health Care | CHF 2.5B | CHF 6.4B | CHF 18.41 | 3.36% up | 83% up | ||
| 26 | United TherapeuticsUTHR · Health Care | CHF 2.7B | CHF 20.8B | CHF 488.12 | 0.90% down | 23% up | ||
| 27 | BioMarin PharmaceuticalBMRN · Health Care | CHF 2.7B | CHF 10.1B | CHF 51.90 | 5.20% up | 11% up | ||
| 28 | Dr. Reddy's LaboratoriesRDY · Health Care | CHF 3B | CHF 10.5B | CHF 12.63 | 1.28% up | 5% up | ||
| 29 | Alnylam PharmaceuticalsALNY · Health Care | CHF 3.1B | CHF 16.9B | CHF 125.98 | 4.54% down | 66% down | ||
| 30 | GenmabGMAB · Health Care | CHF 3.1B | CHF 26.6B | CHF 43.09 | 1.66% down | 70% up | ||
| 31 | Jazz PharmaceuticalsJAZZ · Health Care | CHF 3.6B | CHF 13.3B | CHF 207.69 | 2.32% up | 37% up | ||
| 32 | Elanco Animal HealthELAN · Health Care | CHF 4B | CHF 11.3B | CHF 22.58 | 3.60% up | 20% up | ||
| 33 | BeOne MedicinesONC · Health Care | CHF 4.5B | CHF 38.8B | CHF 339.97 | 2.44% down | 17% up | ||
| 34 | GrifolsGRFS · Health Care | CHF 7B | CHF 4.9B | CHF 7.14 | 1.91% down | 1% up | ||
| 35 | ZoetisZTS · Health Care | CHF 8B | CHF 29.3B | CHF 72.19 | 2.55% up | 29% down | ||
| 36 | Vertex PharmaceuticalsVRTX · Health Care | CHF 10.1B | CHF 115B | CHF 453.49 | 0.67% up | 27% up | ||
| 37 | ViatrisVTRS · Health Care | CHF 12.1B | CHF 19.7B | CHF 17.15 | 0.54% down | 96% up | ||
| 38 | Regeneron PharmaceuticalsREGN · Health Care | CHF 12.1B | CHF 82.5B | CHF 797.41 | 1.27% down | 36% up | ||
| 39 | Teva Pharmaceutical IndustriesTEVA · Health Care | CHF 14.6B | CHF 41.5B | CHF 35.58 | 1.01% down | 74% up | ||
| 40 | Takeda PharmaceuticalTAK · Health Care | CHF 23.8B | CHF 57.2B | CHF 17.92 | 1.83% down | 54% up | ||
| 41 | GSKGSK · Health Care | CHF 36.6B | CHF 82.2B | CHF 41.02 | 1.22% down | 6% up | ||
| 42 | Abbott LaboratoriesABT · Health Care | CHF 37.4B | CHF 152.9B | CHF 88.27 | 0.03% down | 17% down | ||
| 43 | Novo NordiskNVO · Health Care | CHF 38.7B | CHF 146.7B | CHF 33.29 | 3.01% down | 17% down | ||
| 44 | Bristol-Myers SquibbBMY · Health Care | CHF 40.6B | CHF 102.7B | CHF 50.27 | 2.84% down | 34% up | ||
| 45 | SanofiSNY · Health Care | CHF 40.8B | CHF 95.5B | CHF 39.76 | 0.79% down | 4% down | ||
| 46 | NovartisNVS · Health Care | CHF 46B | CHF 247.4B | CHF 130.99 | 2.39% down | 25% up | ||
| 47 | AstraZenecaAZN · Health Care | CHF 49.5B | CHF 233.8B | CHF 150.78 | 1.90% down | 2% up | ||
| 48 | AbbVieABBV · Health Care | CHF 51.6B | CHF 426.1B | CHF 241.04 | 2.38% down | 26% up | ||
| 49 | PfizerPFE · Health Care | CHF 52.8B | CHF 134.7B | CHF 23.64 | 1.55% down | 14% up | ||
| 50 | Merck & CoMRK · Health Care | CHF 54.8B | CHF 286.3B | CHF 116.14 | 3.93% down | 51% up | ||
| 51 | Eli LillyLLY · Health Care | CHF 55B | CHF 1.04T | CHF 1,166.96 | 2.24% down | 35% up | ||
| 52 | Johnson & JohnsonJNJ · Health Care | CHF 79.4B | CHF 554.4B | CHF 230.31 | 2.00% down | 38% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8433 CHF). 9 companies have no revenue on file and are not ranked here.
Questions and answers
Which pharmaceutical companies have the lowest revenue?
Spyre Therapeutics (CHF 0), Praxis Precision Medicines (CHF 0) and Dianthus Therapeutics (CHF 1.7M) have the lowest revenue of the 52 pharmaceutical companies ranked here as of 18 Nov 2026, 20:50 UTC.
How many pharmaceutical companies are in this ranking?
52 are ranked by revenue. 9 more have no revenue on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 52 pharmaceutical companies ranked by revenue have a combined market value of CHF 4.27T as of 18 Nov 2026, 20:50 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest pharmaceutical companies by revenue”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.